<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03539432</url>
  </required_header>
  <id_info>
    <org_study_id>20-018</org_study_id>
    <nct_id>NCT03539432</nct_id>
  </id_info>
  <brief_title>Exploration of Gemfibrozil as a Treatment for AUD</brief_title>
  <official_title>Exploration of Gemfibrozil as a Treatment for Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Mind Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Mind Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the efficacy of the medication gemfibrozil in reducing alcohol
      consumption in individuals with an alcohol use disorder who are seeking treatment for
      alcohol-related problems. Twenty individuals will be randomized to receive four weeks of
      either gemfibrozil or placebo and retrospective reports of alcohol use will be collected
      throughout the trial. In addition, brain imaging measures will be collected at baseline and
      after two weeks of treatment to determine the effects of gemfibrozil on brain functioning.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drinks per drinking day</measure>
    <time_frame>Baseline</time_frame>
    <description>Average number of standard drinks consumed on drinking days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drinks per drinking day</measure>
    <time_frame>2 weeks post baseline</time_frame>
    <description>Average number of standard drinks consumed on drinking days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drinks per drinking day</measure>
    <time_frame>4 weeks post baseline</time_frame>
    <description>Average number of standard drinks consumed on drinking days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drinks per drinking day</measure>
    <time_frame>6 weeks post baseline</time_frame>
    <description>Average number of standard drinks consumed on drinking days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent days abstinent</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of days of abstinence from alcohol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent days abstinent</measure>
    <time_frame>2 weeks post baseline</time_frame>
    <description>Percentage of days of abstinence from alcohol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent days abstinent</measure>
    <time_frame>4 weeks post baseline</time_frame>
    <description>Percentage of days of abstinence from alcohol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent days abstinent</measure>
    <time_frame>6 weeks post baseline</time_frame>
    <description>Percentage of days of abstinence from alcohol</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Gemfibrozil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemfibrozil 600 mg by mouth twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemfibrozil 600 MG</intervention_name>
    <description>Gemfibrozil capsules (600 mg) taken twice per day</description>
    <arm_group_label>Gemfibrozil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Microcrystalline cellulose powder packaged in capsules identical to the experimental medication</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. males and females age 18-60 meeting DSM-V criteria for moderate or severe AUD in the
             past year

          2. interested in cutting down or quitting drinking

          3. able to provide voluntary informed consent

          4. have at least 4 heavy drinking days (â‰¥ 5 drinks per day for men, and 4 for women) in
             the past 30 days

        Exclusion Criteria:

          1. severe liver disease; severe kidney disease; gallbladder disease or gallstones

          2. chronic renal or hepatic failure

          3. recent pancreatitis

          4. insulin-dependent diabetes

          5. other urgent medical problems

          6. moderately elevated liver function tests (AST or ALT greater than 2 times upper limit
             of normal) or elevated creatine kinase (CK)

          7. schizophrenia, schizoaffective disorder, Bipolar I disorder, suicidal thoughts in the
             last month

          8. current moderate or severe other substance use disorder (SUD; except nicotine or
             marijuana)

          9. active legal problems with the potential to result in incarceration

         10. pregnancy or lactation, or child bearing age and not on birth control or not willing
             to use other birth control methods (e.g. condoms)

         11. current daily use of anti-craving medications, mood stabilizers, benzodiazepines, or
             anti-psychotics

         12. regularly taking a medication contraindicated for use with gemfibrozil including other
             fibrates, statins, repaglinide, or which are believed to interact with gemfibrozil
             such as dasabuvir, dabrafenib, loperamide, montelukast, paclitaxel, pioglitazone,
             rosiglitazone, colestipol, colchicine and warfarin41,68

         13. a history of alcohol withdrawal-induced seizures or delirium tremens (hallucinations,
             disorientation) requiring hospital admission during the last ten years

         14. a history of moderate or severe traumatic brain injury (TBI; loss of consciousness &gt;30
             minutes69)

         15. left-handedness

         16. any contraindications for MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Mind Research Network</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jody Roberts, MS</last_name>
      <phone>505-272-5028</phone>
      <email>jroberts@mrn.org</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Mickey, BA</last_name>
      <phone>505-272-5028</phone>
      <email>jmickey@mrn.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemfibrozil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

